At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed non-small cell lung cancer
- ✓Newly diagnosed or recurrent unresectable stage III or IV disease
- ✓Measurable disease present
- ✓No prior antineoplastic chemotherapy for lung cancer
- ✕Pregnant or lactating females
- ✕Serious cardiovascular disease within the previous six months
- ✕Serious active infection at time of treatment
- ✕Other serious underlying medical condition
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of First-Line Therapy With Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pemetrexed and Gemcitabine for Lung Cancer. Completed, enrolled 72 participants across 1 site.
Detailed Summary
This study is designed to study the role of an active and well-tolerated non-platinum agent, gemcitabine, in a combination regimen with pemetrexed in the first-line treatment of advanced NSCLC. This study will serve to define the role of next generation agents in a new combination regimen in the treatment of advanced NSCLC. This combination regimen may ultimately be important in further expanding treatment options for patients while improving survival, quality of life, and symptom control compared with platinum-based combination regimens - and with acceptable toxicity.
Study Details
Timeline
Interventions
500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
1500mg/m2, 30min IV